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Background: In high-throughput demanding fields, such as biotechnology and structural biology, molecular cloning is
an essential tool in obtaining high yields of recombinant protein. Here, we address recently developed restriction-free
methods in cloning, and present a more cost-efficient protocol that has been optimized to improve both cloning and
clone screening.
Results: In our case study, three homologous β-lactamase genes were successfully cloned using these restriction-free
protocols. To clone the genes, we chose a gene replacement strategy, where the recombinant genes contained
overhangs that targeted a region of the expression vector including a cytotoxin-encoding ccdB-gene.
Conclusion: We provide further evidence that gene replacement can be applied with high-throughput cloning
protocols. Targeting a replacement of the ccdB-gene was found to be very successful for counterselection using
these protocols. This eliminated the need for treatment with the restriction enzyme DpnI that has so far been the
preferred clone selection approach. We thus present an optimized cloning protocol using a restriction-free ccdB-gene
replacement strategy, which allows for parallel cloning at a high-throughput level.
Keywords: Restriction-free cloning, Exponential megapriming PCR, High-throughput, Counterselection, Recombinant
DNA technology, Parallel cloningBackground
To meet the demands in biotechnology and structural
biology, high-throughput molecular cloning methods
have been developed to obtaining sufficient amounts of
recombinant protein in a parallel manner. For this pur-
pose, restriction-free (RF) cloning is a simple PCR-based
approach for inserting any DNA fragment into any pos-
ition of a vector, independently of restriction-sites, ligation,
without elaborate pretreatments of the vector and without
sequence constraints [1-3]. Today’s high fidelity polymer-
ases used for cloning have extraordinary low error rates.
Therefore, PCR amplification of large DNA regions, such
as entire plasmids, is no longer challenging. The RF-
method relies on site-specific insertion of the gene of inter-
est to the vector by linear plasmid amplification [2,3].* Correspondence: gro.bjerga@uni.no
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unless otherwise stated.Briefly, the insertion requires that the gene of interest is
flanked by sequences complimentary to the insertion site
of the vector. These overhang regions are generated during
a standard PCR amplification from the relevant template
using primers containing both a gene-specific region and
an adapter region. Finally, the amplified gene with over-
hangs is used as a megaprimer in the second PCR, where
the insertion takes place during linear plasmid amplifica-
tion. The complementary DNA products form a plasmid
containing two single-stranded nicks, which is ready for
transformation and clone screening. To shorten the proto-
col, the gene-specific and the linear plasmid amplification
can be combined in a single PCR reaction. Exponential
megapriming PCR (EMP) cloning addresses the major
shortcoming of the published RF-cloning protocol, the
product- and size-limiting linear plasmid amplification, by
introducing a reverse vector-specific primer making the
amplification exponential [4]. This protocol, however, re-
quires two additional, successive steps of phosphorylation
and ligation to close the plasmid. The fact that thesetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the vector, is in great contrast to other high-throughput
cloning methods, such as TA-cloning and ligation-
independent cloning [5-7]. This makes these protocols
beneficial for many high-throughput applications, such as
structural genomics and biotechnology.
The RF- and EMP-protocols rely on a screening
process to select positive clones from background
clones. This screening includes treating the product mix
from the second PCR with the restriction enzyme DpnI
[8]. The enzyme will remove the methylated parental
DNA before transformation, such as established for the
mutagenesis protocol [9,10]. Typically, DpnI is incubated
with the substrate at 37°C for an hour. The efficiency is
improved by longer incubations, up to several hours, with
the risk of over-digestion. Also, efficiency of DpnI is
dependent on buffer and the methylation state of the
template DNA, and requires vector propagation in Dam+
strains [11].
In our study, we have tested an alternative selection
approach using the coupled cell division B gene (ccdB)
gene, that has previously been reported for recombina-
tional cloning and, more recently, the sequence and
ligation independent cloning (SLIC) and fragment ex-
change (FX) cloning [12-16]. The negative selection is
based on the presence of the ccdB-gene in the cloning
region of the vector. In recombinant DNA the toxic
gene becomes replaced with the gene of interest. In
negative clones, however, a lethal protein is encoded
from the ccdB-gene that interferes with the DNA gyrase
activity and cause un-repairable chromosomal damage
to the cell and ultimately cell death [17,18].
In our case study, we have investigated using a gene
replacement principle [2] in combination with negative
ccdB selection to improve the clone screening process
of RF- and EMP-cloning. In this study, three homolo-
gous blaOXA-genes, encoding the oxacillinase (OXA)
β-lactamases OXA-48, −181 and −245 [19-21], were
successfully cloned downstream of a T7 promoter. We
carried out the cloning by replacing a 1.7 kb region of the
Gateway® vector, pDEST17, which is designed for selec-
tion based on the ccdB-gene, with our genes of interest,
not by traditional recombination, but by using the newly
invented RF- and EMP-cloning protocols. We show that
RF- and EMP-cloning protocols can successfully be used
in gene-replacement applications. Such applications
increase the potential of this method in the manipula-
tions of plasmids. Also, we have found that ccdB-se-
lection was a successful approach for clone selection
for the newly invented cloning regime, which eliminates
the need for DpnI removal of parental DNA. Taken to-
gether, we present an improved, cost-efficient and less
labour-intensive cloning protocol, which allows for clon-
ing and screening in a parallel fashion, using ccdB-genereplacement. Our data increase the potential of the clon-
ing method in high-throughput technologies.
Results and discussion
RF-cloning, including the optimized EMP-protocol, is a
simple method for inserting any gene into a vector, inde-
pendently of restriction-sites [2-4]. The benefit of the
method is that is has no requirements for pretreatments
of vector. The method holds a great potential in biotech-
nology, structural biology and other high-throughput
demanding fields.
Using these restriction-free cloning protocols we inserted
the desired 798 bp long, homologous genes, blaOXA-48,
blaOXA-181 and blaOXA-245, downstream of the T7 promoter
by replacing a region of the commercial vector pDEST17,
including the ccdB-gene (principle outlined in Figure 1).
The genes of interest were amplified in a standard PCR
reaction from a genomic DNA template isolated from clin-
ical isolates (Figure 2A). Primers contained both a gene-
specific sequence, which determined the amplification of
the entire reading frame of the gene, and an adapter region
complementary to the insertion site of the vector. Those
two insertion sites were 1744 bp apart in the vector; the
spanned region included the CamR-ccdB cassette. The
amplified genes containing adapter regions were used as
megaprimers in a second PCR, where the insertion and
replacement reaction took place during linear plasmid
amplification (Figure 2B). Although the efficiency of the
amplifications is generally high due to the high fidelity
polymerases, the product amounts generated in the second
PCR can sometimes be low. We assume that product
formation could be reduces due to particularly long or
difficult GC-rich sequence amplifications or due to the
formation of secondary products. This has not been a
subject for investigation in this study, but optimization
with megaprimer and vector concentrations and thermal
cycling conditions may improve product formation. It
may be worth noticing that although products cannot be
observed after separation on a standard gel electrophoresis,
a small amount of product positive clones may still be
generated, as commonly known from site-directed muta-
genesis protocols. To compensate for low product
formation and low colony numbers, exponential plasmid
amplification was applied by introducing a reverse primer
complimentary to the region upstream to the 5′ insertion
site. While the principle of gene replacement has been de-
scribed [2], the replacement of such a large DNA fragment,
constituting almost 30% of the vector, has not previously
been reported. Our data increases the potential of RF- and
EMP-cloning protocols in the generation and manipula-
tions of plasmids.
In the process of selecting positive clones, DpnI treat-
ment is used for the removal of template DNA in the
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Figure 1 Principle of ccdB-gene replacement strategy. The schematic representation of the ccdB-gene replacement strategy follows three
simple steps, two PCR reactions and a direct transformation of the second PCR product. Primers F1 and R1 are used in a gene-specific amplification
in the first PCR round. Gene-specific regions of primers are indicated by thin, green arrows, whereas the introduced overhang regions are coloured
in orange. In the second PCR, the product from the first PCR is used as a megaprimer in linear plasmid amplification. The overhang regions of the
product bind to the desired insertion sites in the vector that flank the ccdB gene. ccdB-gene for negative selection becomes replaced during
amplification of the plasmid. The R2 primer can be used for exponential amplification. Complementary primer-binding regions in the vector are
marked in the same colours as primers. Finally, the parental vector and the product from the second PCR can be transformed directly to competent
cells. Those cells that take up the paternal vector will be subjected to un-repairable chromosomal damage caused by a toxin encoded by
the ccdB-gene, and will ultimately die. Positive clones, however, will survive since the negative selection marker gene has been replaced with the
gene of interest. Generally, input DNA, such as genomic DNA and vector, is coloured in grey to differentiate it from the black-coloured product
DNA. Thin and fat arrows differentiate primers and open reading frames, respectively.
Lund et al. Microbial Cell Factories 2014, 13:38 Page 3 of 7
http://www.microbialcellfactories.com/content/13/1/38procedure is, however, time-consuming and may lead to
over-digestion of positive clones. Furthermore, efficiency
of DpnI depends on buffer composition and the methy-
lation state of the template DNA, and requires that tem-
plate DNA has been propagated in Dam+ strains. In this
report, we have investigated using the gene replacement
principle [2] in combination with negative ccdB selection
[12-15] to improve the clone screening process of RF-
and EMP-cloning protocols (Figure 1). The product
generated in the second PCR during plasmid amplifi-
cation can thus be transformed directly to competent cells
(Figure 1) without the need of DpnI pre-treatment. Positive
clones were identified by standard colony PCR screening
using vector-specific primers flanking the insertion site
(Figure 2C), and confirmed by Sanger sequencing using
the same primers. Generally, cloning was successful inde-
pendently of linear or exponential amplification, judged
from the ratio of positive clones to total screened clones
identified by colony PCR (Table 1). Furthermore, induction
of recombinant OXA-proteins for heterologous expression
in the E. coli BL21Star (DE3) pRARE was confirmed; here,
recombinant OXA-48 is given as an example (Figure 2D).
Isolation from periplasm together with two purification
steps yielded a pure, recombinant protein as determined
by SDS-PAGE analysis (Figure 2E). The recombinant
enzyme displayed activity towards the β-lactam antibiotic
meropenem. Data were fitted to the Michaelis-Menten
equation; Km was calculated to be 18 ± 5 μM and kcat
to 0.23 ± 0.02 s−1, giving a kcat/ Km of 1.2 × 10
4 (M−1 s−1)(Figure 2F). These results are within the same range as
previously reported [22]. Together with sequencing
and expression results, activity data confirm that the
gene replacement strategy was successful for obtaining
recombinant clones of blaOXA-48.
The replaced 1.7 kb region of the pDEST17 vector con-
taining the ccdB-gene is designed to increase the effi-
ciency of clone selection in recombinational cloning [15].
We explored the vectors containing the ccdB-gene for se-
lection using other cloning methods more applicable for
high-throughput cloning, such as the recently developed
RF- and EMP-cloning protocols. These cloning protocols
have not, previously, been reported in combination with
negative ccdB selection. We have also examined ccdB-se-
lection in combination with DpnI restriction using the
EMP cloning protocols. Parental pDEST17-vectors with
frame shifts within the ccdB-gene that would not kill the
cell would thereby be removed. As an example, when the
blaOXA-181 gene was inserted to pDEST17 by our ccdB-
gene replacement strategy using the EMP-cloning proto-
col, thirteen of twenty-nine colonies were confirmed
positive by colony PCR screening using vector-specific
primers flanking the insertion site (Figure 2C, Table 1).
Background clone numbers did not dramatically improve
by additional DpnI treatment. Although the success of
ccdB selection has been reported before [15], we could
confirm that the ccdB counterselection itself was sufficient
for positive clone selection. Similar results were found
when we cloned homologous blaOXA-48-genes using the
Figure 2 ccdB-gene replacement is an efficient cloning strategy
in obtaining active, recombinant OXA-protein. A) Lane 1 shows
the PCR products from blaOXA-181 gene amplification analysed by
agarose gel electrophoresis. M, Perfect DNA 1 KB ladder; relevant bands
are indicated to the right. Arrow indicates the product matching the
expected size, 857 bp. B) Lane 1 shows the PCR products from the
blaOXA-181 gene inserted into pDEST17 by exponential plasmid
amplification and analysed on agarose gel. M, Perfect DNA 1 KB ladder;
relevant bands are indicated to the right. Arrow indicates the plasmid
product matching the expected size, 5408 bp. C) Lane 1–14 shows the
results from colony PCR analysis of clones 1–14. The expected size of the
screened inserts is 948 bp, and arrow indicates the position of products
matching the expected size. D) SDS-PAGE analysis of the expression of
recombinant OXA-48. Lane 1 shows the uninduced control, whereas
lane 2 shows the IPTG-induced recombinant OXA-48 protein expressed
in E. coli strain BL21Star(DE3)pRARE. M, Precision Plus protein standard;
relevant bands are indicated to the right. Arrow indicates the position of
induced protein matching the theoretical mass of OXA-48 with the
leader sequence removed (28 kDa). E) Recombinant OXA-48
protein was isolated from the periplasm, and purified through
two anionic exchange steps. The integrity of the purified protein is
shown in lane 1. M, Precision Plus protein standard; relevant bands
are indicated to the right. F) The β-lactam antibiotic, merope-
nem, is hydrolysed by OXA-48. The hydrolysis velocities (μM/s)
were plotted as a function of Meropenem concentration (μM); the
enzyme follows the Michaelis-Menten kinetics. Based on these data, Km
was calculated to be 18 ± 5 μM and kcat to 0.23 ± 0.02 s
−1, giving a
catalytic efficiency of 1.2 × 104 (M−1 s−1).
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of positive clones to total number of clones tested some
clones seem to fail in the insert replacement, but still es-
cape the ccdB-determined toxicity as determined by nega-
tive PCR colony screen. This can be explained by primer-
dimer products from the first PCR being inserted to the
vector in the second PCR, or simply due to failed colony
inoculation to PCR screening reaction. In our study,
primer-dimer formations may have been relevant for the
gene-specific amplification of blaOXA-181, leading to false
positives in the plasmid amplification and thus a low num-
ber of positive clones to total screened clones. Optimiza-
tions, such as adding dimethyl sulfoxide (DMSO), could be
carried out to reduce the primer-dimer formation during
the gene-specific amplification. In cases where DpnI treat-
ment was not performed, frameshifts or deletion of the
ccdB gene may also have caused false positives.
In one EMP-cloning experiment, eight hundred colonies
were obtained for the DpnI-treated sample, whereas more
than fifteen hundred colonies were obtained for the
untreated sample (Table 1). When selectivity was deter-
mined by colony PCR, the DpnI treated sample did not give
higher score for positive clone selection. Hence, we
hypothesize that DpnI treatment may lead to over-digestion
of DNA, thereby reducing the probability of positive clones.
This hypothesis was, however, not further investigated.
We chose to explore the commercially available
Gateway® vectors encoding a ccdB-gene. For labs that
have already implemented recombinational cloning, our
Table 1 Numbers for ccdB counterselection with or without DpnI for the targets and cloning protocols used
Gene target Cloning technology DpnI treatment Positive/Total screened clones Transformants1
blaOXA-48 RF-cloning - 13/14 n.d.
blaOXA-245 RF-cloning - 12/14 n.d.
blaOXA-48 EMP-cloning - 26/28 1550
blaOXA-48 EMP-cloning + 27/28 800
blaOXA-181 EMP-cloning - 13/29 32
blaOXA-181 EMP-cloning + 11/24 24
1n.d., not determined.
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products into Gateway® expression vectors harbouring
different fusion-tags based on conserved regions shared
among the vectors. Other vector series encoding the
ccdB-gene are, however, academically available [such as
described in 12,16,23].
Conclusions
In our report, we have provided further evidence that
gene replacement can be applied with restriction-free
cloning protocols, thus, increasing the potential of these
methods in the manipulations of plasmids. Also, we have
found that ccdB-selection was a successful method for
clone selection for the newly invented cloning regimes.
Our optimized procedure represents a more efficient,
cost reducing and less labour-intensive approach for
molecular cloning and clone screening. Together with
previous reports, our data confirms and improves the




Primers were designed to replace the ccdB-gene with the
blaOXA-48-genes encoding OXA β-lactamases, OXA-48,
−181 and −245 [GenBank: KC757416, JN205800 and
JX43800, respectively]. The RF-cloning.org webserver [24]
was used to design primers F1 (5′-ATAATTTTGTT
TAACTTTAAGAAGGAGATATACATATGCGTGTATTA
GCCTTATCGG, where italic represents blaOXA gene-
specific region) and R1 (5′-GGCTTTGTTAGCAGCC
TCGAATCACTAGGGAATAATTTTTTCCTGTTTGAG)
complementary to both inserts and vector. Desalted
primers were synthesized by Sigma-Aldrich.
The blaOXA-megaprimers were amplified in 1x HF
Phusion buffer (NEB) using 200 ng genomic DNA from
clinical isolates, 200 μM dNTP (VWR), 0.5 μM of both
primers F1 and R1, and 1U Phusion DNA polymerase
(NEB) in 50 μL final volume. The samples were dena-
tured by heating to 98°C for 30s, followed by 25 cycles
of 8s denaturation at 98°C, 20s annealing at 56°C and
15s elongation at 72°C, and the reaction was terminatedby a final 5 minutes elongation step at 72°C. PCR prod-
ucts were purified by the Nucleo-Spin gel and PCR
cleanup kit (Macherey-Nagel). PCR products were ana-
lyzed by gel electrophoresis (1% agarose).
RF-cloning was performed as described in previous re-
ports [2,3]. The linear amplifications took place in 1x
HF Phusion buffer, using 100 ng megaprimer, 200 μM
dNTP, 1% DMSO (NEB), 25 ng Gateway® pDEST17 vec-
tor (Invitrogen) and 1U Phusion DNA polymerase. The
mixture was heated to 98°C for 30s denaturation, fol-
lowed by 30 cycles of 8s denaturation at 98°C, 20s an-
nealing at 54°C and 107s elongation at 72°C, terminated
by a final 5 minutes elongation step.
Our EMP protocol was performed as described previ-
ously [4], with minor modifications. Exponential amplifi-
cations of the plasmids were performed with 25 ng
megaprimer, and 1x HF Phusion buffer, 200 μM of
dNTP, 0.5 mM of each primer F1 and R2, 25 ng
pDEST17 and 1U Phusion DNA polymerase. Both the
F1- and R1-primers described above carry overhangs
complementary to the insertion site of the vector, in
contrast to the reported EMP-cloning, where F1-primer
is designed without an overhang [4]. Consequently, the
R2-primer (5′-TTCTAGAGGGAAACCGTTGTGGTCT)
was designed complementary to the vector region 5′ to
the F1-primer to ensure an exponential amplification.
The samples were denatured at 98°C for 30s, followed
by 25 cycles of 10s denaturation at 98°C, 30s annealing
at 56°C and 107s elongation at 72°C.
The EMP products were first purified as described
above, then phosphorylated and ligated by incubating
16.5 μL PCR-product in 1.7 μL 10xT4 DNA ligase buffer
(NEB) with 5U T4 polynucleotide kinase (NEB) for
30 minutes at 37°C, followed by the addition of 6U T4
DNA ligase (NEB) and overnight incubation at 4°C.
For DpnI treatment, 20U enzyme (NEB) was added
directly to half of the PCR product and incubated at 37°C
for 30 minutes. 2 μL reaction products, DpnI treated or
not, was then transformed by a conventional heat-shock
protocol to competent E. coli XL1Blue cells (Stratagene).
The mix of transformed bacteria was spread on an LB-agar
plate supplemented with 100 μg/ml ampicillin (Sigma).
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specific T7 promoter primer (5′-TAATACGACTCACTA
TAGGG) and T7 terminator primer (5′-GCTAGTTAT
TGCTCAGCGG) in 1x Amplicon Taq DNA polymerase
master mix (Ampliqon). Sequences were verified by
BigDye 3.1 sequencing (Applied Biosystems).
Recombinant expression
The purified plasmids containing the blaOXA-48 gene
were transformed to E. coli strain BL21Star(DE3)pRARE
[Invitrogen, Novagen and 25] competent cells by a con-
ventional heat-shock protocol. Cells were used to inocu-
late 1 L Terrific Broth (TB) media containing 100 μg/ml
ampicillin and 34 μg/ml chloramphenicol. Recombinant
expression of native OXA-48 was induced by 0.4 mM
isopropyl-β-D-thiogalactopyranoside (VWR) at log phase,
and expression was continued at 20°C for 16 hours. OXA-
48 was isolated from the periplasm using osmotic shock
and lysozyme-treatment [26], and purified through two an-
ionic exchange steps, as described previously [27].
Kinetics
The purified OXA-48 enzyme was used to determine the
kinetic parameters for hydrolysis of the substrate mero-
penem (Sigma) using a Synergy H1 spectrophotometer
(BioTek) by measuring the change in absorbance at
300 nm. A plate specific extinction coefficient of 0.002733
OD/μM was used for the UV-plates (Corning). Initial rates
were calculated for meropenem concentrations 125-1 μM
with 500 nM enzyme in 100 mM Tris-H2SO4 pH 7,
300 mM Na2SO4 and 10 mM NaHCO3 using Gen5
(BioTek). The steady-state parameters were calculated
with non-linear regression using Prism 6 (GraphPad
Software).
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